Anticyclic citrullinated peptide antibody and rheumatoid factor in South Tunisian patients with rheumatoid arthritis: Association with disease activity and severity

Journal of Clinical Laboratory Analysis

Volumn 28, Issue 1, 2014, Pages 21-26

  Hamad, Mariem Ben ^a   Marzouk, Sameh ^b   Kaddour, Neila ^b   Masmoudi, Hatem ^c   Fakhfakh, Faiza ^a   Rebai, Ahmed ^d   Bahloul, Zouhir ^b   Maalej, Abdellatif ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

^b HEDI CHAKER HOSPITAL   (Tunisia)

^c HABIB BOURGUIBA HOSPITAL   (Tunisia)

^d CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

Author keywords

Anti CCP antibodies; DAS28; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL FEATURE; DAS28; DISABILITY SEVERITY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING STIFFNESS; PAIN ASSESSMENT; RATING SCALE; RHEUMATOID ARTHRITIS; TUNISIA; VAN DER HEIJDE SCORE;

ANTI-CCP ANTIBODIES; DAS28; RHEUMATOID ARTHRITIS; RHEUMATOID FACTOR;

ANTIBODIES; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; REGRESSION ANALYSIS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TUNISIA;

EID: 84892470951     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21638     Document Type: Article

References (47)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-911.
2. Grossman JM, Brahn E. Rheumatoid arthritis: Current clinical and research directions. J Womens Health 1997;6(6):627-638.
3. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373(9664):659-672.
4. Turesson C, O'Fallon MW, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extra articular disease manifestation is associated with excess mortality in a community-based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62-67.
5. Ábalos Medina GM, Ruiz Villaverde G, Sánchez Cano D, et al. The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study. Reumatol Clin 2011;7(3):167-171.
6. Doeglas DM, Suurmeijer TP, van den Heuvel WJ, et al. Functional ability, social support, and depression in rheumatoid arthritis. Qual Life Res 2004;13(6):1053-1065.
7. Gåfvels C, Hägerström M, Nordmark B, Wändell PE. Psychosocial problems among newly diagnosed rheumatoid arthritis patients. Clin Rheumatol 2012;31:521-529.
8. Treharne GJ, Lyons AC, Booth DA, Kitas GD. Psychological well-being across 1 year with rheumatoid arthritis: Coping resources as buffers of perceived stress. Br J Health Psychol 2007;12:323-345.
9. Klaassen K, Nyklíček I, Traa S, de Nijs R. Distressed personality is associated with lower psychological well-being and life satisfaction, but not disability or disease activity in rheumatoid arthritis patients. Clin Rheumatol 2012;31:661-667.
10. Van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93.
11. Westwood OMR, Nelson PN, Hay FC. Rheumatoid factors: What's new? Rheumatology 2006;45:379-385.
12. Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 2002;4(Suppl. 2):S1-S5.
13. Dörner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004;16:246-253.
14. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-594.
15. Zendman AJ, Vossenaar ER, van Venrooij WJ. Autoantibodies to citrullinated (poly)peptides: A key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 2004;37:295-299.
16. Zendman AJW, van Venrooij WJ, Pruijn GJM. Use and significance of anti-CCP autoantibodies in rheumatoid arhritis. Rheumatology 2006;45:20-25.
17. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-163.
18. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004;4:239-262.
19. Afzal N, Karim S, Mahmud TE, Sami W, Arif M, Abbas S. Evaluation of anti-CCP antibody for diagnosis of rheumatoid arthritis. Clin Lab 2011;57:895-899.
20. Basu PS, Majhi R, Ghosal S, Batabyal SK. Peptidyl-arginine deiminase: An additional marker of rheumatoid arthritis. Clin Lab 2011;57:1021-1025.
21. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-2749.
22. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004;50(2):380-386.
23. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002;46:906-912.
24. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-126.
25. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004;50:709-715.
26. del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: Relation with disease aggressiveness. Clin Exp Rheumatol 2006;24(3):281-286.
27. Kim HH, Kim J, Park SH, Kim SK, Kim OD, Choe JY. Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. Korean J Intern Med 2010;25(2):201-206.
28. Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N. Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: Association with disease parameters and quality of life. Clin Rheumatol 2012;31(2):329-334.
29. Bukhari M, Harrison B, Lunt M, Scott DG, Symmons DP, Silman AJ. Time to first occurrence of erosions in inflammatory polyarthritis: Results from a prospective community-based study. Arthritis Rheum 2001;44(6):1248-1253.
30. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-2581.
31. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
32. Hazes JM, Hayton R, Burt J, Silman AJ. Consistency of morning stiffness: An analysis of diary data. Br J Rheumatol 1994;33:562-565.
33. Dougados M, Ripert M, Hilliquin P, et al. The influence of the definition of patient global assessment in assessment of disease activity according to the Disease Activity Score (DAS28) in rheumatoid arthritis. J Rheumatol 2011;38(11):2326-2328.
34. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20(3):579-581.
35. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9(5):789-793.
36. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27(1):261-263.
37. Forslind K, Ahlmen M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum 2004;63:1090-1095.
38. Baan H, Drossaers-Bakker W, Dubbeldam R, van de Laar M. We should not forget the foot: Relations between signs and symptoms, damage, and function in rheumatoid arthritis. Clin Rheumatol 2011;30(11):1475-1479.
39. Goetz I, Carter GC, Lucero M, et al. Review of treatment response in rheumatoid arthritis: Assessment of heterogeneity. Curr Med Res Opin 2011;27(4):697-711.
40. Vanichapuntu M, Phuekfon P, Suwannalai P, Verasertniyom O, Nantiruj K, Janwityanujit S. Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population? Rheumatol Int 2010;30:755-759.
41. Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord 2007;8:37. doi:10.1186/1471-2474-8-37.
42. Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: Diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 2008;37:329-336.
43. Önder B, Kurtaran A, Kimyon S, Selçuk B, Akyüz M. Association of anti-CCP positivity with serum ferritin and DAS-28. Rheumatol Int 2009;30:223-227.
44. Ghosh A, Ghosh B, Pain S, et al. Comparison between DAS28, CDAI and HAQ-DI as tools to monitor early rheumatoid arthritis patients in eastern India. Indian Journal of Rheumatology 2011;6(3):116-122.
45. Khan NA, Yazici Y, Calvo-Alen J, et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol 2009;36(11):2435-2442.
46. Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-3782.
47. Alessandri C, Bombardieri M, Papa N et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-1221.